The Pfizer Research Grant Programme funds independent clinical and observational research, primarily in therapeutic areas of interest to Pfizer, such as oncology and rare diseases. It exists to support investigator-initiated studies that advance medical knowledge and potentially inform future treatment paradigms, with a strong emphasis on rigorous methodology and feasibility.
Selection Criteria
- Scientific merit and innovation of the research proposal
- Relevance to Pfizer's therapeutic areas of interest (e.g., multiple myeloma, elranatamab)
- Feasibility of the study design and timeline
- Qualifications and track record of the principal investigator
- Adequacy of budget and resources
- Potential impact on clinical practice or patient outcomes
Past Winners / Cohort Profiles
Past winners are typically independent clinical researchers or academic investigators with a strong publication record in the relevant therapeutic area. Named examples are not publicly listed on the page, but the archetype is a mid-career or senior researcher with prior grant management experience and a clear, hypothesis-driven study design.
Ideal Candidate Fingerprint
The ideal applicant is an established clinical researcher with a proven track record in the specific disease area (e.g., multiple myeloma), affiliated with a recognized academic or clinical institution, and proposing a well-powered, methodologically sound observational or interventional study that aligns with Pfizer's strategic research priorities.
Recommended Framing
Eniola should frame the CCT model as a novel, hypothesis-driven pharmacological framework that could inform future clinical research in addiction neuroscience, a field with high unmet need. While the grant's stated focus is on elranatamab in multiple myeloma, Eniola can emphasize the transferable rigor of his Bayesian-calibrated ODE modeling and pre-registered methodology, positioning the CCT work as a foundational step toward independent clinical research that aligns with Pfizer's broader interest in advancing discovery through rigorous science.
Watch Out
The grant's explicit focus on elranatamab in relapsed/refractory multiple myeloma is a significant mismatch with Eniola's research on addiction neuroscience and computational pharmacology. Eniola is an independent researcher without institutional affiliation (aside from upcoming MSc enrollment), which may be a disadvantage for a programme that typically funds established clinical investigators. The deadline (June 12, 2026) is very close, leaving little time to tailor a competitive proposal.